| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514110200 | Growth-hormone-releasing hormone (GHRH) or derivative | 14 |
| 20110021429 | Renoprotection by growth hormone-releasing hormone and agonists - The present invention relates to renoprotection by growth hormone-releasing hormone and agonists. More specifically, the present invention relates to methods for protecting a mammal against oxidative renal damage, of promoting regeneration of kidney cells in a mammal in need thereof and/or of preventing the death of kidney cells due to oxidative stress. The present invention also relates to the identification of rat and human renal GHRH-R sequences. | 01-27-2011 |
| 20110112020 | MEASUREMENT OF G-PROTEIN mRNA IN THE DIAGNOSIS OF GROWTH HORMONE INSUFFICIENCY - The present invention is directed towards a diagnostic test, treatment, and monitoring of treatment for growth hormone abnormalities including Growth Hormone Deficiency (“GHD”) as well as a kit comprising the necessary components of the present invention. G-protein expression and levels of mRNA are evaluated to determine if a patient has GHD or if treatment for GHD is effective. A G-protein agonist or antagonist is used to treat GHD by bringing G-protein expression and levels of mRNA into the normal range. | 05-12-2011 |
| 20120004174 | GH SECRETAGOGUES AND USES THEREOF - The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject. | 01-05-2012 |
| 20120108511 | PREPARATION OF BIODEGRADABLE POLYESTERS WITH LOW-BURST PROPERTIES BY SUPERCRITICAL FLUID EXTRACTION - The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues. | 05-03-2012 |
| 20120270784 | GROWTH HORMONE RELEASING FACTOR (GRF) ANALOGS AND USES THEREOF - Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system. | 10-25-2012 |
| 20130261058 | ACCELERATION OF WOUND HEALING BY GROWTH HORMONE RELEASING HORMONE AND ITS AGONISTS - Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists. | 10-03-2013 |
| 20140057847 | CARDIOPROTECTIVE EFFECTS OF GHRH AGONISTS - Disclosed herein are methods demonstrating that growth-hormone releasing hormone (GHRH) directly activates cellular reparative mechanisms within the injured heart, in a GH/IGF-I independent fashion. Following experimental myocardial infarction (MI), rats were randomly assigned to receive, during a 4 week period, either placebo (n=14), rat recombinant GH (rrGH, n=8) or JI-38 (n=8; 50 μg/Kg/day), a potent GHRH-agonist. JI-38 did not elevate serum levels of GH or IGF-I, but markedly attenuated the degree of cardiac functional decline and remodeling after injury. In contrast, GH administration markedly elevated body weight, heart weight, circulating GH and IGF-I, but did not offset the decline in cardiac structure and function. Whereas, both JI-38 and GH augmented levels of cardiac precursor cell proliferation, only JI-38 increased anti-apoptotic gene expression. Collectively, these findings demonstrate that within the heart, GHRH-agonists can activate cardiac repair following MI. | 02-27-2014 |
| 20140179604 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS - Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide. | 06-26-2014 |
| 20140249083 | FORMULATIONS OF GROWTH HORMONE RELEASING FACTOR (GRF) MOLECULES WITH IMPROVED STABILITY - Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a β-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn | 09-04-2014 |
| 20140323402 | Protein Carrier-Linked Prodrugs - The present invention relates to water-soluble protein carrier-linked prodrugs wherein the protein carrier comprises an amino acid sequence consisting of at least 100 amino acid residues forming random coil conformation and comprising alanine, serine and proline residues. It further relates to pharmaceutical compositions comprising said water-soluble protein carrier-linked prodrugs, their use as a medicament as well as methods of treatment and administration. | 10-30-2014 |
| 20140378380 | USE OF UNACYLATED GHRELIN, FRAGMENTS AND ANALOGS THEREOF AS ANTIOXIDANT - The present invention relates to methods for protecting a subject, tissues and/or organs from a subject against oxidative stress-induced damage, such as but not limited to, oxidative stress-induced tissue damage. The method comprises administering an effective amount of unacylated ghrelin, a fragment thereof, an analog thereof and/or pharmaceutically acceptable salts thereof to the subject. | 12-25-2014 |
| 20150031615 | Growth Hormone Releasing Peptides - Disclosed are peptide and peptidomimetic compounds generally according to formula (I) that are useful as GHRP analogs: | 01-29-2015 |
| 20160082123 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs - The present invention relates to a process for the preparation of a hydrogel-linked prodrug releasing a tag moiety-biologically active moiety conjugate, to a hydrogel-linked prodrug releasing a tag moiety-bio logically active moiety conjugate obtainable by such process, to pharmaceutical compositions comprising said prodrug and their use as a medicament. | 03-24-2016 |
| 20160166652 | NOVEL N- AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH | 06-16-2016 |
